← Home / Aptevo Therapeutics Inc. (APVO)
Stock Analysis
Aptevo Therapeutics Inc. (APVO)
APVO
APVO · Market data
4.11 -0.48%
Track APVO in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when APVO price is:
52W Range Position
0%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:43 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
4.60
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
30
●
Material Agreement
MEDIUM
APVO material agreement
On June 29, 2026, Aptevo Therapeutics Inc.
8-K Filing • SEC EDGAR
MAY
27
◆
M&A
HIGH
APVO merger or acquisition update
Collaboration Agreement and Supply Agreement with Niowave On May 25, 2026, Aptevo Research and Development LLC (“Aptevo Research”), a subsidiary of Aptevo Therapeutics Inc.
8-K Filing • SEC EDGAR
MAY
27
◈
Strategic Agreement
HIGH
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
50/50 strategic collaboration will develop up to three radiopharmaceutical programs Innovation and investment continue to accelerate across radiopharmaceutical oncology SEATTLE, WA and LANSING, MI – May 27, 2026 – Aptevo Therapeutics Inc.
8-K Filing • SEC EDGAR
What's Driving APVO?
📈 Technical recovery is improving
Momentum is Neutral. Watch 4.60 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
40.9
Price Chart
APVO — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$4.9M
Company size
EV
$-6.1M
Debt-adjusted value
P/E
-0.2
Not meaningful
P/S
1.6
Low sales multiple
P/B
0.4
Low book multiple
EV/Sales
-2.0
Not meaningful
EV/EBIT
0.2
Low multiple
P/FCF
-0.2
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
3.11M
≈ Insufficient
📈 Net Income
-6.70M
↘ Negative
🧮 EPS (Basic)
-6.41
↘ Negative
Aptevo Therapeutics Inc.
Related Opportunities